top of page

SITC 2024: With a TIL therapy having made it to the market for the first time this year, the CEO of KSQ Therapeutics describes what the next generation of TILs might look like

  • Nov 8, 2024
  • 1 min read

Qasim Rizvi says he believes TILs can have broad applicability in the solid tumor space. He describes how KSQ is knocking out SOCS1 and REGNASE-1 to solve the problem of T-cell exhaustion. The company's first two programs are now in the clinic.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTV

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC_IB_Stacked_logo.png

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

​

​Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

Learn more

bottom of page